Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 31
Filtrar
1.
Molecules ; 28(14)2023 Jul 24.
Artículo en Inglés | MEDLINE | ID: mdl-37513484

RESUMEN

Eriobotrya japonica (loquat tree) has been used in traditional medicine to treat respiratory ailments, inflammation, and skin diseases; however, its potential antidepressant-like effects have not been extensively investigated. In this study, we evaluated the antidepressant-like effects of E. japonica fruit extract (EJFE) in a mouse model of corticosterone (CORT)-induced depression. An HPLC analysis revealed that chlorogenic acid (CGA) is the major compound in EJFE. Male ICR mice (5weeks-old) were injected with CORT (40 mg/kg, intraperitoneally) once daily for 21 days to induce depressive-like behaviors. Various behavioral tests, including the open field test, rotarod test, elevated plus maze (EPM), passive avoidance test (PAT), tail suspension test (TST), and forced swim test (FST), were conducted 1 h after the oral administration of EJFE at different doses (30, 100, and 300 mg/kg) and CGA (30 mg/kg). High-dose EJFE and CGA significantly alleviated CORT-induced depressive-like behaviors, as indicated by the reduced immobility times in the TST and FST. A decrease in the step-through latency time in the PAT, without an effect on locomotor activity, suggested an improvement in cognitive function. Moreover, EJFE- and CGA-treated mice exhibited significantly reduced anxiety-like behaviors in the EPM. Our results imply the promising potential of EJFE containing CGA as a therapeutic candidate for depression.


Asunto(s)
Ácido Clorogénico , Depresión , Animales , Ratones , Depresión/inducido químicamente , Depresión/tratamiento farmacológico , Depresión/psicología , Ácido Clorogénico/farmacología , Conducta Animal , Ratones Endogámicos ICR , Antidepresivos/farmacología , Corticosterona/efectos adversos , Modelos Animales de Enfermedad
2.
Molecules ; 27(11)2022 May 26.
Artículo en Inglés | MEDLINE | ID: mdl-35684372

RESUMEN

Excessive corticosterone (CORT), resulting from a dysregulated hypothalamic-pituitary-adrenal (HPA) axis, is associated with cognitive impairment and behavioral changes, including depression. In Korean oriental medicine, Pedicularis resupinata is used for the treatment of inflammatory diseases such as rheumatoid arthritis. However, the antidepressant properties of P. resupinata have not been well characterized. Here, the antidepressant-like effects of P. resupinata extract (PRE) were evaluated in terms of CORT-induced depression using in vivo models. HPLC confirmed that acteoside, a phenylethanoid glycoside, was the main compound from PRE. Male ICR mice (8 weeks old) were injected with CORT (40 mg/kg, i.p.) and orally administered PRE daily (30, 100, and 300 mg/kg) for 21 consecutive days. Depressive-like behaviors were evaluated using the open-field test, sucrose preference test, passive avoidance test, tail suspension test, and forced swim test. Treatment with a high dose of PRE significantly alleviated CORT-induced, depressive-like behaviors in mice. Additionally, repeated CORT injection markedly reduced brain-derived neurotrophic factor levels, whereas total glucocorticoid receptor (GR) and GR phosphorylation at serine 211 were significantly increased in the mice hippocampus but improved by PRE treatment. Thus, our findings suggest that PRE has potential antidepressant-like effects in CORT-induced, depressive-like behavior in mice.


Asunto(s)
Corticosterona , Pedicularis , Animales , Antidepresivos/farmacología , Antidepresivos/uso terapéutico , Conducta Animal , Corticosterona/efectos adversos , Depresión/inducido químicamente , Depresión/tratamiento farmacológico , Depresión/psicología , Modelos Animales de Enfermedad , Hipocampo , Masculino , Ratones , Ratones Endogámicos ICR , Sistema Hipófiso-Suprarrenal , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Receptores de Glucocorticoides
3.
Oxid Med Cell Longev ; 2021: 9981480, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34257825

RESUMEN

BACKGROUND: Inflammatory bowel disease (IBD) is a result of a complex interplay, making development of a specific treatment a challenging task. Corticosterone was considered a risk factor of stress relative enteritis. Our previous studies found that melatonin exerts an improvement effect in sleep deprivation (SD)- induced corticosterone overproduction and colitis. A present study further explored the mechanism whereby melatonin prevented corticosterone-mediated SD-induced colitis. METHODS: A 72-hour SD mouse model with or without melatonin supplementation and fecal microbiota transplantation (FMT) to investigate the core role of corticosterone in melatonin-mediated gut microbiota improving SD-induced colitis. Further, corticosterone-treated mice were assessed to the effect of melatonin on corticosterone-mediated gut microbiota dysbiosis-induced colitis. Meanwhile, an in vitro test studied modulatory mechanism of metabolite melatonin. RESULTS: SD caused an excessive corticosterone, gut microbiota disorder and colitis phenotype. Similarly, corticosterone-supplemented mice also exhibited gut microbiota dysbiosis and colitis, and the FMT from SD-mice to normal mice could restore the SD-like colitis, but no change in the corticosterone level, which suggested that corticosterone-mediated intestinal microbiota imbalance plays a central role in SD-induced colitis. Further, we demonstrated melatonin-mediated MT2 weakened GR feedback, suppressed oxidative stress, restored the intestinal microbiota and its metabolites homeostasis, and inactivated the STAT3/AP-1/NF-κB pathway-induced inflammatory response in vivo and in vitro. CONCLUSIONS: We revealed that excessive corticosterone is a core risk factor for SD-induced colitis and provided a better understanding of the effects of melatonin, expected to be a personalized targeted therapy drug, on corticosterone-mediated gut microbiota inducing colitis.


Asunto(s)
Antioxidantes/uso terapéutico , Colitis/inducido químicamente , Corticosterona/efectos adversos , Microbioma Gastrointestinal/efectos de los fármacos , Melatonina/uso terapéutico , Privación de Sueño/tratamiento farmacológico , Animales , Antioxidantes/farmacología , Modelos Animales de Enfermedad , Masculino , Melatonina/farmacología , Ratones , Estrés Oxidativo
4.
Sci Rep ; 11(1): 13776, 2021 07 02.
Artículo en Inglés | MEDLINE | ID: mdl-34215821

RESUMEN

Glucocorticoids (GCs) are widely prescribed anti-inflammatory medicines, but their use can lead to metabolic side-effects. These may occur through direct actions of GCs on peripheral organs, but could also be mediated by the hypothalamic AgRP neurons, which can increase food intake and modify peripheral metabolism. Therefore, the aim of this study was to examine the metabolic effects of chronic treatment with the GC corticosterone (Cort, 75 µg/ml in drinking water) in mice lacking the glucocorticoid receptor (GR) on AgRP neurons. Female AgRP-GR KO mice had delayed onset of Cort-induced hyperphagia. However, AgRP-GR KO had little impact on the increased body weight or adiposity seen with 3 weeks Cort treatment. Cort caused hepatic steatosis in control mice, but in Cort treated female AgRP-GR KO mice there was a 25% reduction in liver lipid content and lower plasma triglycerides. Additionally, Cort treatment led to hyperinsulinaemia, but compared to controls, Cort-treated AgRP-GR KO mice had both lower fasting insulin levels and lower insulin levels during a glucose tolerance test. In conclusion, these data indicate that GCs do act through AgRP neurons to contribute, at least in part, to the adverse metabolic consequences of chronic GC treatment.


Asunto(s)
Proteína Relacionada con Agouti/genética , Glucocorticoides/efectos adversos , Inflamación/tratamiento farmacológico , Receptores de Glucocorticoides/genética , Animales , Corticosterona/efectos adversos , Corticosterona/farmacología , Modelos Animales de Enfermedad , Glucocorticoides/farmacología , Humanos , Hiperinsulinismo/inducido químicamente , Hipotálamo/efectos de los fármacos , Hipotálamo/patología , Inflamación/complicaciones , Inflamación/patología , Lípidos/genética , Hígado/efectos de los fármacos , Hígado/patología , Ratones , Neuronas/efectos de los fármacos , Neuronas/patología
5.
Nutrients ; 12(12)2020 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-33266322

RESUMEN

Neuronal cell death induced by chronic stress in the central nervous system is a cause of neurological dysfunction. We investigated the neuroprotective potential of a water extract of S. takesimense (WEST) against corticosterone-induced apoptosis in PC12 cells and the possible underlying mechanisms. Cells were pretreated with 50 µg/mL of WEST to evaluate its neuroprotective effect based on endoplasmic reticulum (ER) stress inhibition and mitochondrial function improvement. Pretreatment with WEST prevented corticosterone-induced injury in PC12 cells, resulting in increased cell survival, decreased lactate dehydrogenase (LDH) release, and potent apoptosis inhibition by a reduction in apoptotic nuclei demonstrated by Hoechst 33,342 and propidium iodide (PI) double staining, and TUNEL staining. WEST strongly attenuated calcium (Ca2+) elevation, inducing the closure of mitochondrial permeability transition pores (mPTPs), which were opened by corticosterone. It also stabilized mitochondrial membrane potential (MMP) loss and inhibited the corticosterone-induced decrease in adenosine triphosphate (ATP) levels. Furthermore, the increased reactive oxygen species (ROS) production induced by corticosterone was prevented in PC12 cells treated with WEST. WEST also downregulated the expression of glucose-regulated protein 78 (GRP78), growth arrest- and DNA damage-inducible gene 153 (GADD153), the pro-apoptotic protein Bcl-2-associated X (Bax), cytochrome c, cysteine-aspartic protease (caspase)-9, and caspase-3, and upregulated the expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). Thus, WEST exerts a neuroprotective effect by inhibiting the apoptosis pathway in ER stress and the mitochondrial dysfunction induced by corticosterone. These results demonstrate that WEST reduces neuronal damage from the neurotoxicity caused by chronic stress.


Asunto(s)
Apoptosis/efectos de los fármacos , Corticosterona/efectos adversos , Fármacos Neuroprotectores/farmacología , Sedum/química , Adenosina Trifosfato/metabolismo , Animales , Caspasa 3/genética , Caspasa 3/metabolismo , Caspasa 9/genética , Caspasa 9/metabolismo , Supervivencia Celular/efectos de los fármacos , Citocromos c/genética , Citocromos c/metabolismo , Estrés del Retículo Endoplásmico/efectos de los fármacos , Regulación de la Expresión Génica , Proteínas de Choque Térmico/genética , Proteínas de Choque Térmico/metabolismo , L-Lactato Deshidrogenasa/metabolismo , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Células PC12 , Extractos Vegetales/análisis , Extractos Vegetales/farmacología , Ratas , Especies Reactivas de Oxígeno/metabolismo , Factor de Transcripción CHOP/genética , Factor de Transcripción CHOP/metabolismo , Proteína X Asociada a bcl-2/genética , Proteína X Asociada a bcl-2/metabolismo
6.
BMC Complement Med Ther ; 20(1): 340, 2020 Nov 11.
Artículo en Inglés | MEDLINE | ID: mdl-33176761

RESUMEN

BACKGROUND: Hericium erinaceus is a culinary and medicinal mushroom in Traditional Chinese Medicines. It has numerous pharmacological effects including immunomodulatory, anti-tumour, anti-microbial, anti-aging and stimulation of nerve growth factor (NGF) synthesis, but little is known about its potential role in negating the detrimental effects of oxidative stress in depression. The present study investigated the neuroprotective effects of H. erinaceus standardised aqueous extract (HESAE) against high-dose corticosterone-induced oxidative stress in rat pheochromocytoma (PC-12) cells, a cellular model mimicking depression. METHODS: PC-12 cells was pre-treated with HESAE for 48 h followed by 400 µM corticosterone for 24 h to induce oxidative stress. Cells in complete medium without any treatment or pre-treated with 3.125 µg/mL desipramine served as the negative and positive controls, respectively. The cell viability, lactate dehydrogenase (LDH) release, endogenous antioxidant enzyme activities, aconitase activity, mitochondrial membrane potentials (MMPs), intracellular reactive oxygen species (ROS) levels and number of apoptotic nuclei were quantified. In addition, HESAE ethanol extract was separated into fractions by chromatographic methods prior to spectroscopic analysis. RESULTS: We observed that PC-12 cells treated with high-dose corticosterone at 400 µM had decreased cell viability, reduced endogenous antioxidant enzyme activities, disrupted mitochondrial function, and increased oxidative stress and apoptosis. However, pre-treatment with HESAE ranging from 0.25 to 1 mg/mL had increased cell viability, decreased LDH release, enhanced endogenous antioxidant enzyme activities, restored MMP, attenuated intracellular ROS and protected from ROS-mediated apoptosis. The neuroprotective effects could be attributed to significant amounts of adenosine and herierin III isolated from HESAE. CONCLUSIONS: HESAE demonstrated neuroprotective effects against high-dose corticosterone-induced oxidative stress in an in vitro model mimicking depression. HESAE could be a potential dietary supplement to treat depression.


Asunto(s)
Corticosterona/efectos adversos , Hericium/química , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Adenosina/farmacología , Agaricales/química , Animales , Apoptosis/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Neuronas/citología , Neuronas/metabolismo , Células PC12 , Pironas/farmacología , Ratas , Especies Reactivas de Oxígeno/metabolismo
7.
Food Funct ; 10(10): 6779-6791, 2019 Oct 16.
Artículo en Inglés | MEDLINE | ID: mdl-31576875

RESUMEN

Glucocorticoids (GCs) are widely used as anti-inflammatory and immunosuppressive drugs. However, chronic treatment with GCs in clinical settings has a series of side effects, such as metabolic disorders, gut microbiota dysbiosis and neurological impairment. Therefore, searching for a functional substance that can alleviate these side effects is greatly meaningful to clinical patients. Crocin is the main active ingredient of saffron, which has been reported to have numerous pharmacological activities. However, the action of crocin-I, one major member of the crocin family, on the physiological mediation in the individuals receiving GC treatment remains unclear. In this study, we aimed to evaluate the efficacy of crocin-I on lipid metabolism and the gut microbiota in a mouse model of chronic corticosterone (CORT) treatment. Our findings showed that crocin-I reduced the levels of triglycerides and total cholesterol and the ratio of low density lipoprotein to high density lipoprotein in the serum of CORT-treated mice. In addition, transcriptome analysis revealed that crocin-I was effective in mediating the amelioration of lipid metabolism, mainly in fatty acid metabolism and steroid biosynthesis in CORT-treated mice. Moreover, metabolome analysis demonstrated that crocin-I could restore the disturbed metabolites in the liver of CORT-treated mice, most of which are long-chain fatty acids. Furthermore, high-throughput sequencing of 16s rRNA revealed that crocin-I could mitigate the dysbiosis of the gut microbiota caused by CORT at a dose of 40 mg kg-1, by resulting in a significant increase in the alpha diversity of the microbes in the cecal contents and a significant reduction in the abundance of Firmicutes, whereas by increasing the abundance of Bacteroidetes. These results indicated that oral administration of crocin-I could modify the composition of the gut microbiota and alleviate hepatic lipid disorder in mice treated with a high dose of GCs.


Asunto(s)
Carotenoides/farmacología , Corticosterona/efectos adversos , Disbiosis/tratamiento farmacológico , Microbioma Gastrointestinal/efectos de los fármacos , Metabolismo de los Lípidos/efectos de los fármacos , Animales , Bacterias/clasificación , Bacterias/genética , Bacteroidetes , Colesterol/sangre , Colon/efectos de los fármacos , Colon/patología , Crocus/química , Modelos Animales de Enfermedad , Ácidos Grasos/metabolismo , Firmicutes , Glucocorticoides/efectos adversos , Glucocorticoides/farmacología , Lipogénesis/efectos de los fármacos , Lipoproteínas LDL/sangre , Hígado/efectos de los fármacos , Hígado/metabolismo , Masculino , Ratones , Ratones Endogámicos C57BL , ARN Ribosómico 16S/genética , Transcriptoma , Triglicéridos/sangre
8.
Biomed Chromatogr ; 33(9): e4542, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-30947404

RESUMEN

A highly selective and efficient LC-MS/MS method was developed to determine the plasma concentration of magnolol, hesperidin, neohesperidin and geniposide following oral administration of Zhi-Zi-Hou-Po decoction in normal and depressed rats. Plasma samples were pretreated by protein precipitation with methanol. Chromatographic separation was performed on an XTerra® MS C18 column using a gradient elution with a mobile phase composed of acetonitrile-0.1% aqueous formic acid. The proposed method was validated to be specific, accurate and precise for the analytes determination in plasma samples. The calibration curves displayed good linearity over definite concentration ranges for the analytes. The intra- and inter-day precision of the proposed method at three different levels were all within <11.13% and the relative errors ranged from -8.46 to 8.93%. The recovery of the four compounds ranged from 82.72 to 89.08% and no apparent matrix effect was observed during sample analysis. After full validation, the established method was successfully applied for comparing the pharmacokinetics of four components between normal and depressed rats. The results showed that the AUC and Cmax of four analytes in depressed rats were significantly different from those in normal rats and might provide helpful information to guide the clinical use of Zhi-Zi-Hou-Po to treat depression.


Asunto(s)
Depresión , Medicamentos Herbarios Chinos/farmacocinética , Iridoides/farmacocinética , Administración Oral , Animales , Compuestos de Bifenilo/sangre , Compuestos de Bifenilo/química , Compuestos de Bifenilo/farmacocinética , Corticosterona/efectos adversos , Depresión/inducido químicamente , Depresión/metabolismo , Modelos Animales de Enfermedad , Medicamentos Herbarios Chinos/administración & dosificación , Hesperidina/sangre , Hesperidina/farmacocinética , Iridoides/administración & dosificación , Iridoides/sangre , Iridoides/química , Lignanos/sangre , Lignanos/química , Lignanos/farmacocinética , Límite de Detección , Modelos Lineales , Masculino , Ratas , Ratas Sprague-Dawley , Reproducibilidad de los Resultados
9.
Molecules ; 24(3)2019 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-30754635

RESUMEN

Three previously undescribed iridoids, cornusfurals A⁻C, were isolated from the ethanolic extracts of fruits of Cornus officinalis. Their structures were elucidated by spectroscopic methods, including one-dimensional and two-dimensional nuclear magnetic resonance, ultraviolet spectroscopy, infrared spectroscopy, and mass spectrometry. The neuroprotective activity was evaluated by measuring corticosterone-induced damage in PC12 cells. The results showed that cornusfural B decreased corticosterone-induced PC12 cell damage compared with that in model cells.


Asunto(s)
Cornus/química , Corticosterona/efectos adversos , Iridoides/aislamiento & purificación , Iridoides/farmacología , Neuronas/citología , Animales , Etanol/química , Etanol/aislamiento & purificación , Frutas/química , Iridoides/química , Espectroscopía de Resonancia Magnética , Espectrometría de Masas , Estructura Molecular , Neuronas/efectos de los fármacos , Neuroprotección , Células PC12 , Extractos Vegetales/química , Ratas , Espectrofotometría Infrarroja
10.
J Nutr ; 148(3): 316-325, 2018 03 01.
Artículo en Inglés | MEDLINE | ID: mdl-29546310

RESUMEN

Background: We have shown previously that in ovo betaine injection can prevent nonalcoholic fatty liver induced by glucocorticoid exposure in chickens; yet it remains unknown whether feeding betaine to laying hens may exert similar effects in their progeny. Objective: In this study, we fed laying hens a betaine-supplemented diet, and the progeny were later exposed chronically to corticosterone (CORT) to test hepatoprotective effects and further elucidate underlying mechanisms. Methods: Rugao yellow-feathered laying hens (n = 120) were fed a basal (control, C) diet or a 0.5% betaine-supplemented (B) diet for 28 d before their eggs were collected for incubation. At 49 d of age, male chickens selected from each group were daily injected subcutaneously with solvent (15% ethanol; vehicle, VEH) or CORT (4.0 mg/kg body mass) for 7 d to establish a fatty liver model. Chickens in the 4 groups (C-VEH, C-CORT, B-VEH, and B-CORT) were killed at day 57. Plasma and hepatic triglyceride (TG) concentrations, as well as the hepatic expression of genes involved in lipogenesis and lipophagy, were determined. Results: CORT induced a 1.6-fold increase in the plasma TG concentration (P < 0.05) and a 1.8-fold increment in the hepatic TG concentration (P < 0.05), associated with activation of lipogenic genes (70-780%). In contrast, lipophagy and mitochondrial ß-oxidation genes were inhibited by 30-60% (P < 0.05) in CORT-treated chickens. These CORT-induced changes were completely normalized by maternal betaine supplementation or were partially normalized to intermediate values that were significantly different from those in the C-VEH and C-CORT groups. These effects were accompanied by modifications in CpG methylation and glucocorticoid receptor binding to the promoters of major lipogenic and lipophagic genes (P < 0.05). Conclusions: These results indicate that maternal betaine supplementation protects male juvenile chickens from CORT-induced TG accumulation in the liver via epigenetic modulation of lipogenic and lipophagic genes.


Asunto(s)
Betaína/uso terapéutico , Corticosterona/efectos adversos , Suplementos Dietéticos , Hígado Graso/prevención & control , Hígado/efectos de los fármacos , Fenómenos Fisiologicos de la Nutrición Prenatal , Triglicéridos/metabolismo , Animales , Betaína/farmacología , Pollos , Corticosterona/metabolismo , Metilación de ADN/efectos de los fármacos , Modelos Animales de Enfermedad , Epigénesis Genética , Hígado Graso/etiología , Hígado Graso/metabolismo , Femenino , Metabolismo de los Lípidos/efectos de los fármacos , Metabolismo de los Lípidos/genética , Lipogénesis/efectos de los fármacos , Lipogénesis/genética , Hígado/metabolismo , Masculino , Mitocondrias , Proteínas Mitocondriales/genética , Embarazo , Regiones Promotoras Genéticas , Receptores de Glucocorticoides/metabolismo
11.
Poult Sci ; 97(6): 2095-2105, 2018 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-29514276

RESUMEN

Broilers were used to determine the protective effects of Forsythia suspensa extract (FSE) against breast muscle oxidative injury induced by corticosterone (CS) mimicking pre-slaughter acute stress. A total of 144 male Arbor Acre broilers was randomly allotted to one of 4 treatments in a 2 × 2 factorial arrangement that included FSE supplementation (0 or 100 mg/kg) and subcutaneous injection of CS (0 or 4 mg/kg) at 3 h before slaughter. Corticosterone increased live BW loss, and the adverse effect was attenuated by FSE in broilers subjected to CS (P < 0.05). Serum levels of CS, uric acid, and glucose were increased, and postmortem breast muscle pH values at 45 min and 24 h were decreased for CS-challenged broilers (P < 0.05). Corticosterone increased lightness and yellowness values and decreased redness of breast muscle (P < 0.05), and FSE decreased yellowness and increased redness of breast muscle (P < 0.05). Drip loss was increased by CS for birds supplemented without FSE (P < 0.05) and decreased by FSE for birds under CS challenge (P < 0.05). Corticosterone increased monounsaturated fatty acid (FA) and decreased polyunsaturated FA in breast muscle (P < 0.05), and saturated FA was decreased and polyunsaturated FA was increased by FSE (P < 0.05). Malondialdehyde and carbonyl contents in breast muscle were increased by CS and decreased by FSE (P < 0.05). Inhibition of 1,1-diphenyl-2-picryl-hydrazyl was decreased by CS and increased by FSE (P < 0.05). The activities of total-antioxidant capacity, glutathione peroxidase, and superoxide dismutase in breast muscle were lower in birds subjected to CS (P < 0.05) and were greater in birds supplemented with FSE (P < 0.05). Collectively, live BW loss and breast muscle oxidative injury were increased by CS in broilers, and these stress-related adverse effects could be attenuated by FSE supplementation via enhanced scavenging ability of free radicals and antioxidant capacity. Therefore, FSE could protect broilers against breast muscle oxidative injury when acute stress happens.


Asunto(s)
Pollos/fisiología , Forsythia/química , Estrés Oxidativo/efectos de los fármacos , Músculos Pectorales/fisiología , Extractos Vegetales/farmacología , Sustancias Protectoras/farmacología , Estrés Fisiológico , Alimentación Animal/análisis , Animales , Corticosterona/administración & dosificación , Corticosterona/efectos adversos , Dieta/veterinaria , Suplementos Dietéticos/análisis , Inyecciones Subcutáneas/veterinaria , Masculino , Extractos Vegetales/administración & dosificación , Sustancias Protectoras/administración & dosificación , Distribución Aleatoria
12.
Phytother Res ; 31(9): 1341-1348, 2017 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-28656606

RESUMEN

To further explore the underlying antidepressant mechanism of ginseng total saponins (GTS), this study observed the effects on hippocampal astrocyte structural plasticity and hippocampal volume in the corticosterone-induced mouse depression model. Corticosterone (20 mg/kg/day) was administered subcutaneously for 5 weeks, and GTS (12.5, 25, and 50 mg/kg/day; namely GTSL, GTSM, and GTSH) or fluoxetine (10 mg/kg/day) were given intragastrically during the last 3 weeks. On day 33 and day 34, depression-like behavior was observed via a forced swimming test and a tail suspension test, respectively. At 6 h after the last dose of corticosterone (day 35), all mice were sacrificed followed by serum corticosterone assays, stereological analysis of hippocampal glial fibrillary acidic protein-positive (GFAP+ ) astroctyes and hippocampal volume, and hippocampal glycogen tests. Results showed that all doses of GTS ameliorated depression-like behavior and the decrease in hippocampal glycogen without normalizing hypercortisolism. Moreover, GTSH and GTSM reversed the corticosterone-induced reduction in the total number of hippocampal GFAP+ astrocytes and hippocampal volume. Additionally, GTSH alleviated the diminished protrusion length and somal volume of GFAP+ astrocytes induced by corticosterone. These findings imply that the effects of GTS on corticosterone-induced depression-like behavior may be mediated partly through the protection to hippocampal astrocyte structural plasticity. Copyright © 2017 John Wiley & Sons, Ltd.


Asunto(s)
Antidepresivos/farmacología , Astrocitos/efectos de los fármacos , Corticosterona/efectos adversos , Hipocampo/efectos de los fármacos , Panax/química , Saponinas/farmacología , Animales , Atrofia , Corticosterona/sangre , Depresión/inducido químicamente , Modelos Animales de Enfermedad , Fluoxetina/farmacología , Proteína Ácida Fibrilar de la Glía/metabolismo , Suspensión Trasera , Hipocampo/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Natación
13.
Int J Nanomedicine ; 11: 4975-4990, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27757031

RESUMEN

Major depression is a complex neuropsychiatric disorder with few treatment approaches. The use of nontargeted antidepressants induced many side effects with their low efficacy. A more precise targeting strategy is to develop nanotechnology-based drug delivery systems; hence, we employed solid lipid nanoparticles (SLNs) to encapsulate HU-211 and curcumin (Cur). The antidepressant effects of the dual-drug nanoparticles (Cur/SLNs-HU-211) for major depression treatment were investigated in corticosterone-induced cellular and animal models of major depression. Cur/SLNs-HU-211 can effectively protect PC12 cells from corticosterone-induced apoptosis and can release more dopamine, which may be associated with the higher uptake of Cur/SLNs-HU-211 shown by cellular uptake behavior analysis. Additionally, Cur/SLNs-HU-211 significantly reduced the immobility time in forced swim test, enhanced fall latency in rotarod test, and improved the level of dopamine in mice blood. Cur/SLNs-HU-211 can deliver more Cur to the brain and thus produce a significant increase in neurotransmitters level in brain tissue, especially in the hippocampus and striatum. The results of Western blot and immunofluorescence revealed that Cur/SLNs-HU-211 can significantly enhance the expression of CB1, p-MEK1, and p-ERK1/2. Our study suggests that Cur/SLNs-HU-211 may have great potential for major depression treatment.


Asunto(s)
Antidepresivos/uso terapéutico , Corticosterona/efectos adversos , Curcumina/uso terapéutico , Trastorno Depresivo Mayor/tratamiento farmacológico , Dronabinol/análogos & derivados , Sistemas de Liberación de Medicamentos , Lípidos/química , Nanopartículas/química , Animales , Western Blotting , Peso Corporal/efectos de los fármacos , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Supervivencia Celular/efectos de los fármacos , Curcumina/farmacología , Trastorno Depresivo Mayor/sangre , Modelos Animales de Enfermedad , Dopamina/sangre , Dronabinol/química , Liberación de Fármacos , Femenino , Técnica del Anticuerpo Fluorescente , Ratones Endogámicos C57BL , Nanopartículas/ultraestructura , Neurotransmisores/metabolismo , Células PC12 , Ratas , Solubilidad , Distribución Tisular/efectos de los fármacos
14.
BMC Complement Altern Med ; 15: 210, 2015 Jul 03.
Artículo en Inglés | MEDLINE | ID: mdl-26138544

RESUMEN

BACKGROUND: Repeated injection of corticosterone (CORT) induces dysregulation in the hypothalamic-pituitary-adrenal (HPA) axis, resulting in depression. We examined the effects of Angelica gigas extract (AGN) treatment in a rat model of depressive and anxiety-like behaviors, induced by chronic CORT exposure. METHODS: Male rats received 10, 20, or 50 mg/kg AGN (i.p.) 30 min prior to a daily injection of CORT for 21 consecutive days. Activation of the HPA axis in response to the repeated CORT injections was confirmed by measuring serum levels of CORT and the expression of corticotropin-releasing factor in the hypothalamus. RESULTS: Daily AGN administration significantly reversed the depression and anxiety-like behavioral abnormalities. It also blocked increases in tyrosine hydroxylase expression in the locus coeruleus, and suppressed the decreased expression levels of brain-derived neurotrophic factor (BDNF) and its receptor TrkB mRNAs in the hippocampus. CONCLUSIONS: These findings indicate that administration of AGN prior to high-dose exogenous CORT significantly improved helpless behaviors, possibly by modulating the central noradrenergic system and regulation of BDNF expression in rats. Thus, AGN may be a useful agent for the treatment or alleviation of psychiatric disorders associated with depression and anxiety disorders.


Asunto(s)
Angelica , Corticosterona , Depresión/tratamiento farmacológico , Extractos Vegetales , Animales , Conducta Animal/efectos de los fármacos , Corticosterona/administración & dosificación , Corticosterona/efectos adversos , Modelos Animales de Enfermedad , Masculino , Extractos Vegetales/administración & dosificación , Extractos Vegetales/farmacología , Extractos Vegetales/uso terapéutico , Ratas
15.
Sci Rep ; 5: 9442, 2015 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-25801728

RESUMEN

Stress induced constant increase of cortisol level may lead to sleep disorder, but the mechanism remains unclear. Here we described a novel model to investigate stress mimicked sleep disorders induced by repetitive administration of corticosterone (CORT). After 7 days treatment of CORT, rats showed significant sleep disturbance, meanwhile, the glucocorticoid receptor (GR) level was notably lowered in locus coeruleus (LC). We further discovered the activation of noradrenergic neuron in LC, the suppression of GABAergic neuron in ventrolateral preoptic area (VLPO), the remarkable elevation of norepinephrine in LC, VLPO and hypothalamus, as well as increase of tyrosine hydroxylase in LC and decrease of glutamic acid decarboxylase in VLPO after CORT treatment. Microinjection of GR antagonist RU486 into LC reversed the CORT-induced sleep changes. These results suggest that GR in LC may play a key role in stress-related sleep disorders and support the hypothesis that repeated CORT treatment may decrease GR levels and induce the activation of noradrenergic neurons in LC, consequently inhibit GABAergic neurons in VLPO and result in sleep disorders. Our findings provide novel insights into the effect of stress-inducing agent CORT on sleep and GRs' role in sleep regulation.


Asunto(s)
Corticosterona/efectos adversos , Locus Coeruleus/metabolismo , Receptores de Glucocorticoides/metabolismo , Trastornos del Sueño-Vigilia/fisiopatología , Neuronas Adrenérgicas/efectos de los fármacos , Neuronas Adrenérgicas/patología , Animales , Corticosterona/metabolismo , Humanos , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Locus Coeruleus/patología , Mifepristona/administración & dosificación , Ratas , Receptores de Glucocorticoides/antagonistas & inhibidores , Sueño/efectos de los fármacos , Sueño/fisiología , Trastornos del Sueño-Vigilia/inducido químicamente , Trastornos del Sueño-Vigilia/metabolismo
16.
Steroids ; 96: 95-102, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25668613

RESUMEN

Stress in our daily life severely affects the normal physiology of the biological system. Dysregulation of hypothalamic-pituitary-adrenal (HPA) axis has been implicated in the development of depression-like behavior, which remains under diagnosed and poorly treated. Exogenous corticosterone (CORT) administration has been demonstrated to develop a depression model, which has shown to mimic HPA-axis induced depression-like state in rodents. In the present study, the effect of a novel 5HT3 receptor, 4i was examined on CORT induced depression in mice. CORT (30mg/kg, subcutaneously) was given for 4-weeks to mice in control group, while mice in drug treated group were given 4i (0.5-1mg/kg, intraperitoneally)/fluoxetine (as a positive control, 10mg/kg), for the last 2-weeks of CORT dosing. Repeated CORT dosing caused depression-like behavior in mice as indicated by increased despair effects in forced swim test (FST) and anhedonia in sucrose preference test. In addition, CORT administration induced oxidative load in the brain with significant increase in pro-oxidant (lipid peroxidation and nitrite levels) markers and a substantial decline in anti-oxidant defense (catalase and reduced glutathione levels) system, indicating a direct effect of stress hormones in the induction of the brain oxidative damage. On the other hand, 4i and fluoxetine treatment reversed the CORT induced depressive-like deficits. Furthermore, 4i and fluoxetine prevented CORT induced oxidative brain insults, which may plausibly demonstrate one of the key mechanisms for antidepressant-like effects of the compounds. Thus, the study suggests that 5HT3 antagonist; 4i may be implicated as pharmacological intervention targeting depressive-like anomaly associated with HPA-axis dysregulation.


Asunto(s)
Conducta Animal/efectos de los fármacos , Corticosterona/efectos adversos , Depresión/tratamiento farmacológico , Estrés Oxidativo/efectos de los fármacos , Quinoxalinas/farmacología , Receptores de Serotonina 5-HT3/metabolismo , Antagonistas del Receptor de Serotonina 5-HT3/farmacología , Animales , Catalasa/metabolismo , Depresión/inducido químicamente , Depresión/metabolismo , Glutatión/metabolismo , Hipotálamo/efectos de los fármacos , Hipotálamo/metabolismo , Hipotálamo/fisiopatología , Peroxidación de Lípido/efectos de los fármacos , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Nitritos/metabolismo , Sistema Hipófiso-Suprarrenal/efectos de los fármacos , Sistema Hipófiso-Suprarrenal/metabolismo , Sistema Hipófiso-Suprarrenal/fisiopatología , Quinoxalinas/uso terapéutico , Antagonistas del Receptor de Serotonina 5-HT3/uso terapéutico , Natación
17.
Phytomedicine ; 21(11): 1458-65, 2014 Sep 25.
Artículo en Inglés | MEDLINE | ID: mdl-25022209

RESUMEN

Yokukansan, a traditional Japanese herbal medicine, has been used for the management of neurodegenerative disorders and for the treatment of neurosis, insomnia, and behavioral and psychological symptoms of dementia. Recently, several studies have shown that yokukansan has a neuroprotective effect. The aim of this study was to examine the neuroprotective effect of yokukansan on hippocampal neurons from embryonic mouse brain against the effects of corticosterone, which is considered to be a stress hormone and to be cytotoxic toward neurons. The cell survival rates were measured by the WST-8 assay and LDH assay. Twenty-four hours after treatment with corticosterone, cell numbers were significantly decreased compared with the control or treatment with vehicle in a dose-dependent manner. When cells were treated with 30 µM corticosterone, the decrease in the number of cells was significantly recovered by treatment with yokukansan (100-1,000 µg/ml) in a dose-dependent manner. However, yokukansan did not suppress the decrease in cell numbers that was induced by treatment with 100 µM corticosterone. In the LDH assay, treatment with yokukansan at a high concentration (500-1,000 µg/ml) suppressed the LDH concentration induced by treatment with both 30 µM and 100 µM corticosterone compared to treatment with corticosterone alone, respectively. These results suggest that yokukansan protects against the cytotoxic effect of a low concentration of corticosterone on hippocampal neurons.


Asunto(s)
Corticosterona/efectos adversos , Medicamentos Herbarios Chinos/farmacología , Hipocampo/citología , Neuronas/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Animales , Células Cultivadas , Embrión de Mamíferos/citología , Ratones Endogámicos ICR , Cultivo Primario de Células
18.
Biomed Res Int ; 2014: 942927, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24901001

RESUMEN

Oxidative stress is considered to be a mechanism of major depression. Pycnogenol (PYC) is a natural plant extract from the bark of Pinus pinaster Aiton and has potent antioxidant activities. We studied the ameliorative effect of PYC on depression-like behavior in chronic corticosterone- (CORT-) treated mice for 20 days. After the end of the CORT treatment period, PYC (0.2 mg/mL) was orally administered in normal drinking water. Depression-like behavior was investigated by the forced swimming test. Immobility time was significantly longer by CORT exposure. When the CORT-treated mice were supplemented with PYC, immobility time was significantly shortened. Our results indicate that orally administered PYC may serve to reduce CORT-induced stress by radical scavenging activity.


Asunto(s)
Corticosterona/efectos adversos , Depresión/tratamiento farmacológico , Trastorno Depresivo/tratamiento farmacológico , Flavonoides/farmacología , Animales , Antioxidantes/farmacología , Depresión/inducido químicamente , Trastorno Depresivo/inducido químicamente , Modelos Animales de Enfermedad , Masculino , Ratones , Ratones Endogámicos C57BL , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Estrés Psicológico/tratamiento farmacológico , Natación/fisiología
19.
J Nat Med ; 68(1): 132-43, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23749289

RESUMEN

The purpose of this study was to examine whether baicalin (BAI) improves spatial cognitive impairments induced in rats following the repeated administration of the exogenous stress hormone corticosterone (CORT). The effect of BAI on the hippocampal expression of brain-derived neurotrophic factor (BDNF) and cAMP response element-binding protein (CREB) was also investigated. For 21 days, male rats received daily doses of BAI (20, 50, and 100 mg/kg, i.p.) 1 h prior to a CORT (40 mg/kg) injection. The daily administration of BAI improved memory impairment as measured by the passive avoidance test and reduced the escape latency for finding the platform in the Morris water maze test. Additionally, as assessed by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) analysis, the administration of BAI also significantly alleviated memory-associated decreases in the expression levels of BDNF and CREB proteins and mRNAs in the hippocampus. These results demonstrate that the administration of BAI prior to high-dose exogenous CORT results in significant neuroprotective activity against neuronal impairment and memory dysfunction in rats. Thus, these findings suggest that BAI might be useful as a therapeutic agent in various neurodegenerative diseases for the improvement of cognitive function. This likely occurs through the regulation of BDNF and CREB expression.


Asunto(s)
Reacción de Prevención/efectos de los fármacos , Conducta Animal/efectos de los fármacos , Corticosterona , Flavonoides/farmacología , Hipocampo/efectos de los fármacos , Trastornos de la Memoria/tratamiento farmacológico , Memoria/efectos de los fármacos , Fármacos Neuroprotectores/farmacología , Nootrópicos/farmacología , Animales , Factor Neurotrófico Derivado del Encéfalo/genética , Factor Neurotrófico Derivado del Encéfalo/metabolismo , Factor Neurotrófico Derivado del Encéfalo/fisiología , Proteína de Unión a CREB/genética , Proteína de Unión a CREB/metabolismo , Proteína de Unión a CREB/farmacología , Cognición/efectos de los fármacos , Corticosterona/efectos adversos , Hipocampo/metabolismo , Hipocampo/fisiopatología , Masculino , Trastornos de la Memoria/inducido químicamente , Trastornos de la Memoria/genética , Trastornos de la Memoria/metabolismo , Trastornos de la Memoria/fisiopatología , Trastornos de la Memoria/psicología , Actividad Motora/efectos de los fármacos , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Tiempo de Reacción/efectos de los fármacos , Factores de Tiempo
20.
Psychoneuroendocrinology ; 38(6): 871-83, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23044404

RESUMEN

High level of serum corticosteroid is frequently associated with depression, in which a notable HPA (hypothalamus-pituitary-adrenal) axis hyperactivity is often observed. There are two types of corticosteroid receptors expressed in the hippocampus that provide potent negative feedback regulation on the HPA axis but dysfunction during depression, i.e. the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). The balance between hippocampal MR and GR during chronic stress plays an important role in the occurrence of depression. The aim of this study is to explore if chronic corticosterone administration would induce depression-like behavior and affect the expression and function of hippocampal MR and GR, in addition to assess whether manipulation of corticosteroid receptors would modulate depressive behaviors. Hence, mice were treated with corticosterone (40 mg/kg) for 21 days followed by assessment in a battery of depression-like behaviors. The results show that chronic corticosterone-treated animals displayed an increased immobility time in a forced-swimming test, decreased preference to sucrose solution and novel object recognition performance, and enhanced hippocampal serotonin but decreased MR expression in both hippocampus and hypothalamus. On the other hand, co-administration of MR antagonist, spironolactone (25mg/kg, i.p. × 7 days) in corticosteroid-treated animals reduced immobility time in a forced-swimming test and improved performance in a novel object recognition test. In conclusion, we demonstrate that chronic corticosterone treatment triggers several depression-like behaviors, and in parallel, down-regulates MR expression in the hippocampus and hypothalamus. Administration of an MR antagonist confers an anti-depressant effect in chronic corticosterone-treated animals.


Asunto(s)
Corticosterona/antagonistas & inhibidores , Depresión/prevención & control , Hipocampo/metabolismo , Antagonistas de Receptores de Mineralocorticoides/uso terapéutico , Espironolactona/uso terapéutico , Animales , Conducta Animal/efectos de los fármacos , Corticosterona/efectos adversos , Corticosterona/sangre , Depresión/inducido químicamente , Depresión/tratamiento farmacológico , Hipocampo/efectos de los fármacos , Ácido Hidroxiindolacético/metabolismo , Hipotálamo/metabolismo , Masculino , Ratones , Receptores de Glucocorticoides/metabolismo , Receptores de Mineralocorticoides/metabolismo , Serotonina/metabolismo , Proteínas de Transporte de Serotonina en la Membrana Plasmática/metabolismo , Triptófano Hidroxilasa/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA